

Yuan Jian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9495289/publications.pdf>

Version: 2024-02-01

19
papers

139
citations

1306789

7
h-index

1281420

11
g-index

19
all docs

19
docs citations

19
times ranked

280
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma. <i>Medicine (United States)</i> , 2016, 95, e3521.	0.4	24
2	Retrospective analysis of genetic abnormalities and survival in 131 patients with multiple myeloma. <i>Oncology Letters</i> , 2015, 9, 930-936.	0.8	18
3	Immunoparesis in symptomatic multiple myeloma at diagnosis affects PFS with bortezomib-containing induction therapy, but not ASCT consolidation. <i>International Journal of Hematology</i> , 2019, 109, 169-174.	0.7	12
4	Target and resistance-related proteins of recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand on myeloma cell lines. <i>Biomedical Reports</i> , 2016, 4, 723-727.	0.9	10
5	What Multiple Myeloma With t(11;14) Should Be Classified Into in Novel Agent Era: Standard or Intermediate Risk?. <i>Frontiers in Oncology</i> , 2020, 10, 538126.	1.3	10
6	Arsenic trioxide potentiates sensitivity of multiple myeloma cells to lenalidomide by upregulating cereblon expression levels. <i>Oncology Letters</i> , 2017, 14, 3243-3248.	0.8	9
7	Human MutT homologue 1 mRNA overexpression correlates to poor response of multiple myeloma. <i>International Journal of Hematology</i> , 2017, 105, 318-325.	0.7	8
8	Gain of 1q21 is an adverse prognostic factor for multiple myeloma patients treated by autologous stem cell transplantation: A multicenter study in China. <i>Cancer Medicine</i> , 2020, 9, 7819-7829.	1.3	8
9	Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients. <i>Leukemia and Lymphoma</i> , 2021, 62, 883-890.	0.6	7
10	Effect of CYP2C19 and CYP3A4 gene polymorphisms on the efficacy of bortezomib-based regimens in patients with multiple myeloma. <i>Oncology Letters</i> , 2015, 10, 1171-1175.	0.8	6
11	Effects and mechanism of arsenic trioxide in combination with rmhTRAIL in multiple myeloma. <i>Experimental Hematology</i> , 2016, 44, 125-131.e11.	0.2	6
12	Genome-wide discovery and characterization of long noncoding RNAs in patients with multiple myeloma. <i>BMC Medical Genomics</i> , 2019, 12, 135.	0.7	5
13	The Association Between Low T3 Syndrome and Survival in Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210944.	0.8	5
14	Incidence of multiple myeloma in Kailuan cohort: A prospective community-based study in China. <i>Cancer Epidemiology</i> , 2022, 78, 102168.	0.8	4
15	Oligodendroglioma metastasis to the bone marrow mimicking multiple myeloma: A case report. <i>Oncology Letters</i> , 2016, 12, 351-355.	0.8	3
16	Echocardiographyâ€defined pulmonary hypertension is an adverse prognostic factor for newly diagnosed multiple myeloma patients. <i>Cancer Medicine</i> , 2022, 11, 4182-4192.	1.3	3
17	Simultaneous occurrence of splenic diffuse large B cell lymphoma and gastrointestinal stromal tumor in the stomach: a case report. <i>Diagnostic Pathology</i> , 2018, 13, 61.	0.9	1
18	T cell receptor rearrangements in a patient with $\hat{1}^3$ -heavy chain disease: A case report. <i>Oncology Letters</i> , 2016, 11, 4147-4151.	0.8	0

#	ARTICLE	IF	CITATIONS
19	T(4; 14) Is Not a Poor Prognostic Factor for Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation in New Drug Era. Blood, 2020, 136, 30-30.	0.6	0